NASDAQ:EYEN - Eyenovia Stock Price, Forecast & News

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

Eyenovia Inc (NASDAQ:EYEN) released its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.05. View Eyenovia's Earnings History.

Eyenovia is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Eyenovia.

3 brokers have issued 1 year target prices for Eyenovia's stock. Their forecasts range from $9.00 to $10.00. On average, they expect Eyenovia's share price to reach $9.50 in the next year. This suggests a possible upside of 114.9% from the stock's current price. View Analyst Price Targets for Eyenovia.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia.

Media headlines about EYEN stock have been trending positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Eyenovia earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Eyenovia.

Eyenovia saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 257,500 shares, a drop of 8.1% from the January 15th total of 280,300 shares. Based on an average daily volume of 89,700 shares, the short-interest ratio is presently 2.9 days. Currently, 2.7% of the shares of the stock are short sold. View Eyenovia's Current Options Chain.

Some companies that are related to Eyenovia include Wave Life Sciences (WVE), Gemphire Therapeutics (GEMP), Syndax Pharmaceuticals (SNDX), Bicycle Therapeutics (BCYC), IVERIC bio (ISEE), VBI Vaccines (VBIV), MediciNova (MNOV), Avadel Pharmaceuticals (AVDL), Hookipa Pharma (HOOK), Evofem Biosciences (EVFM), Geron (GERN), Kalvista Pharmaceuticals (KALV), Ocular Therapeutix (OCUL), BIOFRONTERA AG/ADR (BFRA) and XOMA (XOMA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Zynerba Pharmaceuticals (ZYNE), Axsome Therapeutics (AXSM), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV), Cara Therapeutics (CARA), Fate Therapeutics (FATE), GW Pharmaceuticals PLC- (GWPH), Iovance Biotherapeutics (IOVA), Ovid Therapeutics (OVID) and Tesla (TSLA).

(EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ served as the underwriters for the IPO.

Eyenovia's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include National Asset Management Inc. (0.07%) and Virtu Financial LLC (0.06%). Company insiders that own Eyenovia stock include Charles E Iv Mather, Curt H Labelle, John P Gandolfo, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View Institutional Ownership Trends for Eyenovia.

EYEN stock was acquired by a variety of institutional investors in the last quarter, including National Asset Management Inc. and Virtu Financial LLC. Company insiders that have bought Eyenovia stock in the last two years include Charles E Iv Mather, Curt H Labelle, John P Gandolfo, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View Insider Buying and Selling for Eyenovia.

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EYEN stock can currently be purchased for approximately $4.42.

Eyenovia has a market capitalization of $72.67 million. The company earns $-17,250,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. View Additional Information About Eyenovia.

The official website for Eyenovia is http://www.eyenoviabio.com/.

Eyenovia's mailing address is 295 Madison Avenue Suite 2400, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]